Cleaning Validation

Cleaning Validation Acceptance Criteria: MACO and Carryover Limits Explained

9 min read By Ahmad Al-Sharif, Senior CSV Consultant

Cleaning validation is a regulatory requirement for any pharmaceutical manufacturing equipment that is shared between products or between batches of the same product. Its purpose is to demonstrate that your cleaning procedure reliably removes product residues, cleaning agents, and microbial contamination to levels that will not affect the safety, quality, or efficacy of the next product manufactured on that equipment.

The most technically demanding aspect of cleaning validation is establishing and justifying the acceptance criteria - the maximum allowable residue levels. This guide explains the regulatory basis for cleaning acceptance criteria, how to calculate MACO, and the practical considerations for choosing between rinse and swab sampling.

Regulatory Basis for Cleaning Validation

EU GMP Annex 15 (2015 revision) provides the most detailed regulatory guidance on cleaning validation in the European context. It requires that cleaning validation studies demonstrate removal of product residues, cleaning agents, and microbial contamination. The FDA's Guide to Inspections of Validation of Cleaning Processes (1993, still current) and the EMA's Guideline on Setting Health-Based Exposure Limits (2014) provide additional technical frameworks.

What Is MACO?

MACO stands for Maximum Allowable Carryover - the maximum amount of a previous product (the "donor product") that is allowed to carry over into the next product (the "recipient product") manufactured on the same equipment.

The traditional MACO calculation uses the lowest of three limits:

  1. The therapeutic dose limit - 0.1% of the minimum therapeutic daily dose of the donor product in the maximum daily dose of the recipient product
  2. The 10 ppm limit - the donor product concentration in the recipient product must not exceed 10 parts per million (10 mg/kg)
  3. The visual limit - no visible residue should remain on equipment surfaces after cleaning

The MACO is the most stringent of these three values - the calculation that results in the lowest permitted carryover.

Health-Based Exposure Limits (HBELs). The EMA's 2014 guideline introduced the concept of health-based exposure limits, calculated from toxicological data (PDE - Permitted Daily Exposure). For highly potent or toxic active substances, the HBEL-based MACO is more stringent than the traditional 0.1% dose and 10 ppm limits. HBEL-based acceptance criteria are now expected for all new cleaning validation studies in Europe.

MACO Calculation: Step by Step

The traditional therapeutic dose-based MACO formula is:

MACO = (TDmin × SF) / LDD

Where:

  • TDmin = the minimum therapeutic daily dose of the donor product
  • SF = safety factor (typically 1/1000 to give 0.001 × TDmin)
  • LDD = the largest daily dose of the recipient product

The result gives the maximum mass of donor product that may appear in one day's dose of the recipient product.

To convert MACO to a surface residue limit (for swab sampling):

Limit (µg/cm²) = MACO / (BSA × SSA)

Where BSA is the batch size of the recipient product and SSA is the shared surface area of the equipment.

Rinse Sampling vs Swab Sampling

The two primary sampling methods for cleaning validation are rinse sampling and swab sampling. Most cleaning validation programmes use both in combination:

  • Rinse sampling - collecting a final rinse sample from the equipment after cleaning and analysing it for residue. Advantages: samples the entire equipment surface; easy to perform. Disadvantages: dilution effect makes detection of low-level residues difficult; does not distinguish between surfaces that are easy vs. difficult to clean.
  • Swab sampling - physically swabbing defined surface areas using a wetted swab and analysing the swab for residue. Advantages: direct surface measurement; identifies difficult-to-clean "worst case" locations; more sensitive than rinse sampling for most analytes. Disadvantages: requires validation of swab recovery efficiency; more labour-intensive; swab recovery varies by surface material.

Regulatory expectation (reflected in EMA and FDA guidance) is that swab sampling is preferred for cleaning validation because it provides direct surface measurement. Rinse sampling alone is generally not acceptable for equipment validation unless it can be justified that all surfaces are equally accessible and rinseable.

Worst-Case Product Selection

Cleaning validation studies are not required for every product manufactured on each piece of equipment - a bracketing or matrix approach using worst-case products is acceptable. Worst-case selection considers:

  • Products with the lowest therapeutic dose (most potent) - set the most stringent MACO
  • Products with the most difficult-to-clean active ingredients (sticky, poorly soluble, or highly coloured)
  • Products with the lowest batch size manufactured on the equipment (least dilution of carry-over)
  • Equipment with the most complex geometry or hardest-to-reach surfaces

Demonstrating cleaning validation for the worst-case product validates the cleaning procedure for all other products in the "family" - provided the cleaning procedure is the same and the products are of similar category.

Free Cleaning Validation MACO Calculator Template

Download our spreadsheet template for MACO calculation - including therapeutic dose method, 10 ppm method, and HBEL comparison, pre-formatted for regulatory documentation.

Download Free Checklist →
Cleaning Validation MACO EU GMP Annex 15 HBEL Swab Sampling Pharmaceutical Manufacturing
A

Ahmad Al-Sharif

Senior CSV Consultant · 12 years in pharmaceutical validation

Ahmad leads PHARPRO's CSV and digital validation practice. He has delivered validation projects across Jordan, UAE, Saudi Arabia, and Europe - covering FDA 21 CFR Part 11, EU GMP Annex 11, and ISPE GAMP 5 frameworks.

Frequently asked questions

Both apply. The traditional limits (0.1% of dose and 10 ppm) are still required as a minimum, but health-based exposure limits (HBELs/PDEs) must also be calculated for all new cleaning validation studies under EMA guidance. If the HBEL-based MACO is more stringent than the traditional limits, the HBEL limit applies. For legacy cleaning validation studies, a risk-based review against HBEL data is expected as part of periodic revalidation.
EU GMP Annex 15 requires a minimum of three consecutive cleaning runs to be validated before a cleaning procedure can be considered validated. These must be performed on the same equipment, using the same cleaning procedure, and using the worst-case product(s) and batch sizes. If any of the three runs fails to meet acceptance criteria, the failure must be investigated and the cleaning procedure modified before restarting the three-run sequence.
Cleaning validation between products does not apply to dedicated equipment (equipment used exclusively for one product). However, cleaning between batches of the same product still requires a validated cleaning procedure. Additionally, environmental controls and cross-contamination controls for dedicated equipment must still be demonstrated. EMA guidance also requires that the rationale for equipment dedication is documented.
The choice of analytical method depends on the residue being measured and the required sensitivity. Common methods include HPLC (for specific product residue quantification), TOC (Total Organic Carbon, for general organic residue), pH and conductivity (for cleaning agent residues), and visual inspection. The analytical method must be validated for its intended use, including recovery efficiency from the specific surfaces sampled.

Ready to work with PHARPRO?

Get a free assessment of your compliance programme - no obligation.

Request Free Assessment Explore QA Services
PHARPRO - Expert Pharma Consulting

Ensure your team understands MACO calculations and cleaning validation protocols. PHARPRO offers instructor-led Cleaning Validation training for pharma teams.

Cleaning Validation Training → Free Assessment
Related Insights

Keep reading

More in-depth guides from the PHARPRO compliance team.

IQ OQ PQ Explained: What Each Phase Requires
Regulatory basis, documentation requirements, and what auditors look for in each qualification phase.
Thermal Mapping for Pharmaceutical Warehouses
When mapping is required, sensor layout design, and what the final report must contain.
What Is a Validation Master Plan?
What a VMP must contain, who owns it, and how to keep it current through the system lifecycle.
What Is a GMP Gap Assessment?
What a gap assessment covers, when to conduct one, and how PHARPRO structures the engagement.
EU GMP Annex 11: A Practical Compliance Checklist
Supplier assessment, validation documentation, audit trails, and data integrity - 2025 edition.